Literature DB >> 19373620

Update on research and treatment of premenstrual dysphoric disorder.

Joanne Cunningham1, Kimberly Ann Yonkers, Shaughn O'Brien, Elias Eriksson.   

Abstract

Many women in their reproductive years experience some mood, behavioral. or physical symptoms in the week prior to menses. Variability exists in the level of symptom burden in that some women experience mild symptoms, whereas a small minority experience severe and debilitating symptoms. For an estimated 5%-8% of premenopausal women, work or social functioning are affected by severe premenstrual syndrome. Many women in this group meet diagnostic criteria for premenstrual dysphoric disorder (PMDD). Among women who suffer from PMDD, mood and behavioral symptoms such as irritability, depressed mood, tension, and labile mood dominate. Somatic complaints, including breast tenderness and bloating, also can prove disruptive to women's overall functioning and quality of life. Recent evidence suggests that individual sensitivity to cyclical variations in levels of gonadal hormones may predispose certain women to experience these mood, behavioral, and somatic symptoms. Treatments include: antidepressants of the serotonin reuptake inhibitor class, taken intermittently or throughout the menstrual cycle; medications that suppress ovarian cyclicity; and newer oral contraceptives with novel progestins.

Entities:  

Mesh:

Year:  2009        PMID: 19373620      PMCID: PMC3098121          DOI: 10.1080/10673220902891836

Source DB:  PubMed          Journal:  Harv Rev Psychiatry        ISSN: 1067-3229            Impact factor:   3.732


  297 in total

1.  The epidemiology of premenstrual symptoms in a population-based sample of 2650 urban women: attributable risk and risk factors.

Authors:  S Ramcharan; E J Love; G H Fick; A Goldfien
Journal:  J Clin Epidemiol       Date:  1992-04       Impact factor: 6.437

2.  Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression.

Authors:  K S Kendler; L M Karkowski; L A Corey; M C Neale
Journal:  Am J Psychiatry       Date:  1998-09       Impact factor: 18.112

3.  Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study.

Authors:  R Schellenberg
Journal:  BMJ       Date:  2001-01-20

4.  Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes.

Authors:  L D Griffin; S H Mellon
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

5.  Lack of effect of induced menses on symptoms in women with premenstrual syndrome.

Authors:  P J Schmidt; L K Nieman; G N Grover; K L Muller; G R Merriam; D R Rubinow
Journal:  N Engl J Med       Date:  1991-04-25       Impact factor: 91.245

6.  Premenstrual symptoms in general practice patients. Prevalence and treatment.

Authors:  E M Campbell; D Peterkin; K O'Grady; R Sanson-Fisher
Journal:  J Reprod Med       Date:  1997-10       Impact factor: 0.142

7.  Self-reported premenstrual exacerbation of depressive symptoms in patients seeking treatment for major depression.

Authors:  S G Kornstein; A T Harvey; A J Rush; S R Wisniewski; M H Trivedi; D S Svikis; N D McKenzie; C Bryan; R Harley
Journal:  Psychol Med       Date:  2005-05       Impact factor: 7.723

Review 8.  Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches.

Authors:  P L Moja; C Cusi; R R Sterzi; C Canepari
Journal:  Cochrane Database Syst Rev       Date:  2005-07-20

9.  Serotonin transporter gene polymorphisms and platelet [3H] paroxetine binding in premenstrual dysphoria.

Authors:  J Melke; L Westberg; M Landén; C Sundblad; O Eriksson; F Baghei; R Rosmond; E Eriksson; A Ekman
Journal:  Psychoneuroendocrinology       Date:  2003-04       Impact factor: 4.905

10.  How does premenstrual dysphoric disorder relate to depression and anxiety disorders?

Authors:  Mikael Landén; Elias Eriksson
Journal:  Depress Anxiety       Date:  2003       Impact factor: 6.505

View more
  34 in total

Review 1.  Cognitive-behavioral and pharmacological interventions for premenstrual syndrome or premenstrual dysphoric disorder: a meta-analysis.

Authors:  Maria Kleinstäuber; Michael Witthöft; Wolfgang Hiller
Journal:  J Clin Psychol Med Settings       Date:  2012-09

Review 2.  A review of estrogen receptor alpha gene (ESR1) polymorphisms, mood, and cognition.

Authors:  Erin E Sundermann; Pauline M Maki; Jeffrey R Bishop
Journal:  Menopause       Date:  2010-07       Impact factor: 2.953

Review 3.  Neuroimaging the Menstrual Cycle and Premenstrual Dysphoric Disorder.

Authors:  Erika Comasco; Inger Sundström-Poromaa
Journal:  Curr Psychiatry Rep       Date:  2015-10       Impact factor: 5.285

4.  Combined Oral Contraceptive Pill Initiation in a Patient With Major Depressive Disorder, Premenstrual Dysphoric Disorder, Social Anxiety, Panic Disorder, and Histrionic Personality Disorder.

Authors:  Cody Roi; Erich J Conrad
Journal:  Ochsner J       Date:  2017

5.  Increased childhood abuse in patients with premenstrual dysphoric disorder in a Turkish sample: a cross-sectional study.

Authors:  Esra Akyol Soydas; Yakup Albayrak; Basak Sahin
Journal:  Prim Care Companion CNS Disord       Date:  2014-07-24

6.  Lifetime discrimination associated with greater likelihood of premenstrual dysphoric disorder.

Authors:  Corey E Pilver; Rani Desai; Stanislav Kasl; Becca R Levy
Journal:  J Womens Health (Larchmt)       Date:  2011-06       Impact factor: 2.681

Review 7.  Premenstrual dysphoric disorder and severe premenstrual syndrome in adolescents.

Authors:  Andrea J Rapkin; Judith A Mikacich
Journal:  Paediatr Drugs       Date:  2013-06       Impact factor: 3.022

Review 8.  The influence of stress at puberty on mood and learning: role of the α4βδ GABAA receptor.

Authors:  S S Smith
Journal:  Neuroscience       Date:  2012-10-16       Impact factor: 3.590

9.  Menstrual mood disorders are associated with blunted sympathetic reactivity to stress.

Authors:  Rebecca R Klatzkin; Adomas Bunevicius; Catherine A Forneris; Susan Girdler
Journal:  J Psychosom Res       Date:  2013-11-12       Impact factor: 3.006

10.  Flumazenil decreases surface expression of α4β2δ GABAA receptors by increasing the rate of receptor internalization.

Authors:  Aarti Kuver; Sheryl S Smith
Journal:  Brain Res Bull       Date:  2015-11-22       Impact factor: 4.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.